Arrivent is a clinical‑stage biopharmaceutical company that identifies, develops, and commercializes differentiated oncology medicines, focusing on hard‑to‑treat cancers. It leverages deep drug‑development and regulatory expertise to advance high‑quality candidates—including next‑generation antibody‑drug conjugates—through in‑licensing, partnerships, and strategic collaborations, aiming to bring effective therapies to global patients.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SIFounders
Product
Problem
Patients with difficult-to-treat cancers often lack effective therapies because many promising drug candidates never progress beyond early research due to limited development resources and regulatory challenges.
Solution
Arrivent is a clinical‑stage biopharmaceutical company that focuses on identifying, developing, and commercializing differentiated oncology medicines. Leveraging deep drug‑development experience and strong regulatory expertise, the company selects high‑quality candidates—regardless of therapeutic class—and advances them through preclinical and clinical stages. Arrivent builds strategic collaborations and in‑licensing agreements to expand its pipeline, including next‑generation antibody‑drug conjugates, while aiming to bring these therapies to global patient populations efficiently.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking development partners, as well as scientific founders with novel oncology assets, and ultimately patients with difficult-to-treat cancers.
Features
- Therapeutic‑class agnostic scouting to source innovative candidates with strong scientific rationale
- In‑licensing and partnership model that accelerates access to promising drug assets
- Experienced regulatory strategy design to streamline approval pathways
- Development of next‑generation antibody‑drug conjugates and other novel oncology therapeutics
- Dedicated focus on unmet medical needs in hard‑to‑treat cancers, exemplified by the lead candidate firmonertinib